

Haematologica
HAEMATOL/2019/228171
Version 4

A laboratory-based scoring system predicts early treatment in Rai 0
chronic lymphocytic leukemia

Jared A. Cohen, Francesca Maria Rossi, Antonella Zucchetto, Riccardo Bomben, Lodovico Terzi-di-Bergamo, Kari G. Rabe, Massimo Degan, Agostino Steffan, Jerry Polesel, Enrico Santinelli, Idanna Innocenti, Giovanna Cutrona, Giovanni D' Arena, Gabriele Pozzato, Francesco Zaja, Annalisa Chiarenza, Davide Rossi, Francesco Di Raimondo, Luca Laurenti, Massimo Gentile, Fortunato Morabito, Antonino Neri, Manlio Ferrarini, Christopher D. Fegan, Christopher J. Pepper, Giovanni Del Poeta, Sameer A. Parikh, Neil E. Kay, and Valter Gattei

Disclosures: For clinical studies in which Sameer A. Parikh is a principal investigator, research funding has been provided from Pharmacyclics, MorphoSys, Janssen, AstraZeneca, and Ascentage Pharma. Sameer A. Parikh has also participated in Advisory Board meetings of Pharmacyclics, AstraZeneca, Genentech, Gilead, and AbbVie (he was not personally compensated for his participation). Neil Kay's work has been funded by Tolero Pharm, Pharmacyclics and Acerta; he has participated in advisory boards for the following companies: Tolero Pharm, Gilead, Celgene, Morpho-sys, In#64257;nity Pharm, Pharmacyclics, Janssen, Cytomx Therapeutics, Agios Pharm and Acerta. The authors declare no additional competing financial interests.

Contributions: JC and VG coordinated and designed the study and wrote the manuscript, MG, CF, CP, SP, and NK provided clinical data, performed data analysis and contributed to manuscript revision, LT, KR, JP performed data analysis, ES, II, GC, GD, GP, FZ, AC, DR, FDR, LL, FM, AN, MF, GDP provided clinical data, FMR, AZ, RC, MD, and AS performed laboratory analysis of relevant prognostic biomarkers. All authors contributed to manuscript revision.